eFFECTOR Appoints Mayank Gandhi, M.D., as Chief Business Officer Portfolio News / By Karina Tin September 26, 2022
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy Portfolio News / By Karina Tin September 26, 2022
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor Portfolio News / By Karina Tin September 22, 2022
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy Portfolio News / By Karina Tin September 21, 2022
Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO Portfolio News / By Karina Tin September 21, 2022
Atavistik Bio Announces Formation of Scientific Advisory Board Portfolio News / By Karina Tin September 20, 2022
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 Portfolio News / By Karina Tin September 14, 2022
Nura Bio reports preclinical data validating a conserved mechanism of inhibition of NAD hydrolases implicated in neurodegeneration in NEURON Portfolio News / By Karina Tin September 13, 2022
NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference Portfolio News / By Karina Tin September 13, 2022
Synthekine Named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022 Portfolio News / By Karina Tin September 12, 2022
